“The Applicant evaluated the safety of sotorasib using Sprague-Dawley rats and Beagle dogs in GLP-compliant repeat-dose toxicology studies of up to 3 months duration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Why that species
Human metabolites formed in vitro were also produced by rat and dog liver microsomes/hepatocytes
“The human metabolites formed in vitro were also produced in the rat and dog in vitro (liver microsomes/hepatocytes).”
✓ VerifiedFDA multi-discipline review, p. 65Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“The Applicant evaluated the safety of sotorasib using Sprague-Dawley rats and Beagle dogs in GLP-compliant repeat-dose toxicology studies of up to 3 months duration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: general tox
Rat and dog (3-month GLP studies)
“The Applicant evaluated the safety of sotorasib using Sprague-Dawley rats and Beagle dogs in GLP-compliant repeat-dose toxicology studies of up to 3 months duration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: DART
Rat and rabbit (EFD)
“The Applicant conducted GLP-compliant embryo-fetal development studies in Sprague-Dawley rats and New Zealand White rabbits.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Species: carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“No carcinogenicity studies have been conducted nor are any planned in accordance with International Council for Harmonisation (ICH) S9 (ICH, 2009).”
✓ VerifiedFDA multi-discipline review, p. 76Source ↗
Surrogate used in
No surrogate used; sotorasib tested directly in rats and dogs
“The Applicant evaluated the safety of sotorasib using Sprague-Dawley rats and Beagle dogs in GLP-compliant repeat-dose toxicology studies of up to 3 months duration.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗